# Spero Therapeutics Posts $0.76 Q3 Loss Per Share, Cash Runway Into 2029

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56026
Published: 2026-11-12T23:15:34.000Z
Updated: 2026-11-12T23:15:34.000Z
Section: Business

> The company had $107.9 million in cash and equivalents on Sept. 30, 2026, and expects the funds to support operations into the second half of 2029.

Spero Therapeutics, Inc. posted a GAAP loss of $0.76 per share for the third quarter of 2026.

The company had $107.9 million in cash and cash equivalents on Sept. 30, 2026. Spero expects its funds to support operations into the second half of 2029.